"Dr. Gupta received his B.S. (Biological Chemistry) from the University of Chicago in 1996. He received his M.D. from the University of Illinois at Chicago in 2002. He then performed his residency in urologic surgery at the University of Maryland Medical Center (2002-2008). He continued his training as a fellow in Urologic Oncology at the National Cancer Institute (NIH) in the Urologic Oncology Branch under the guidance of Dr. W. Marston Linehan (2008-2011). In 2011 he was recruited to the Department of Urology by Dr. Robert Flanigan as a fellowship trained urologic oncologist. Dr. Gupta holds a primary appointment in the Department of Urology, and has a joint appointment in the Department of Surgery, Radiology and the Oncology Institute at the Cardinal Bernardin Cancer Center.
His primary clinical research interests pertain to bladder, kidney and prostate cancer. Dr. Gupta performs minimally invasive surgeries using the DaVinci Robotic Surgery platform. His clinical interests are to push the cutting edge of technology while optimizing cancer outcomes. He has published extensively about varied topics in gentiourinary oncology including: MRI/TRUS fusion ultrasound guided prostate biopsy, Active Surveillance for prostate cancer, optimizing renal functional outcomes for partial nephrectomy, improving surgical decision making in prostate cancer surgery using MRI, health services related research aimed at addressing disparities in care delivery in genitourinary oncology.
Dr. Gupta’s laboratory is located in the oncology institute. He has been named a Dean’s Office Clinical Scholar and splits his time between his clinical responsibilities and his research interests. His laboratory is active in: 1) creating pre-clinical models in bladder and kidney cancer to assess the effects of emerging targeted therapies, 2) understanding the role of cancer shed exosomes as biomarkers, their role in progression of cancer and EMT, 3) the role of hypoxia signaling in renal and bladder malignancy."

Dr. Yuanyuan Zhang is a director of tissue therapy and assistant professor in the Wake Forest Institute for Regeneration Medicine (WFIRM) and department of urology at the University of Wake Forest University, Winston-Salem, North Carolina. He received his M.D. from Jiangxi Medical Collage in China, earned his spot as attending urologist in department of urology at the First Affiliated Hospital in Nanchang University. Dr. Zhang completed his PhD training program in University of Lausanne in Switzerland. After postdoc training, he became a faculty member in department of urology at the University of Oklahoma Health Science Center and then at Wake Forest Institute for Regenerative Medicine, a premier environment for research in stem cell therapy and tissue engineering in genitourinary surgery.

"Dr Kamran Zargar-Shoshtari graduated from the University of Otago in New Zealand. Following his internship he conducted full time clinical research, focusing on strategies to improve care following major abdominal surgery. Dr Zargar-Shoshtari completed urological training in New Zealand and Australia and was awarded Fellowship of Royal Australasian college of Surgeons (FRACS). Following this he received further training in genitourinary oncology at Moffitt cancer center, in Tampa, Florida.

His research interests include various aspects of urologic oncology in particular treatment of bladder and penile cancer.
"

"Robert J. Amato is a Professor in the Department of Internal Medicine and Director of the Division of Oncology at The University of Texas Medical School – Houston and the Memorial Hermann Cancer Center.
He received his D.O. from The University of North Texas in Fort Worth, Texas, in 1983.
He serves as an editorial board member and reviewer for numerous journals and has had more than 300 publications over the course of his career.

Research Interests
Tumor Immunology
Molecular Targeted Therapy
Genitourinary Oncology
"

"Matthew Rutman, M.D., is the Director of Voiding Dysfunction, Incontinence and Urodynamic Center at New York Presbyterian Hospital/Columbia University Medical Center. He is an Associate Professor of Clinical Urology at Columbia University College of Physicians and Surgeons. He graduated with honors from Emory University and The Chicago Medical School. After completing his residency at William Beaumont Hospital, Dr. Rutman completed a fellowship in female urology, voiding dysfunction, neurourology and urodynamics under world renowned Shlomo Raz, M.D at the UCLA Medical Center.
Dr. Rutman is board-certified in urology and female pelvic medicine and reconstructive surgery (FPMRS). His practice is limited to male and female voiding dysfunctions including urinary retention, benign prostatic hyperplasia (BPH), interstitial cystitis, prostatitis, urinary incontinence, overactive bladder, neurogenic bladder, urinary tract infections, and reconstructive female urology surgery for vaginal prolapse, urethral diverticulum and vesico-vaginal fistulae. He has authored over 40 book chapters and publications in leading journals and urology textbooks. His clinical and research interests are in male and female incontinence, vaginal prolapse, voiding dysfunction, urodynamics and surgical outcomes.
Professional Associations:
American Medical Association; Society of Urodynamics and Female Urology; American Urologic Association; Endourology Society; American Urogynecologic Society; International Continence Society; Alpha Omega Alpha Medical Honor Society
"

"Vice director of Shenzhen Luohu Hospital Group(the Fifth People's Hospital of Shenzhen, The Affiliated Luohu Hospital of Shenzhen University),the president of Shenzhen Following Precision Medical Research Institute, M.D., Distinguished Research Fellow, standing vice director of National and local joint key technologies for tumor genomics and clinical application engineering laboratory. Mainly engaged in Urinary system tumor genomics and clinical precision medical research, published in Top international journal Nature genetics, European Urology, Cell research etc 28 achievements as first author or Communication author, total impact factor more over 201. European Urology, Annals of Oncology, Journal of Urology, Urologic Oncology, Journal of Experimental &Clinical Cancer Research and BMC Cancer reviewers, editorial member in Telomere and Telomerease.
Presided over the national natural foundation 1, Shenzhen major technology development projects 1, basic research projects 1, participating in 863, 973 program, Shenzhen technology research 1. 16 patent applications, 3 PCT, 3 invention patents have been approved .
Currently occupy a position as oncology group deputy team leader in Urinary Surgery Branch of Guangdong Medical Association, vice president of Guangdong Urological and Reproductive association, youth committee of Guangdong Anti-Cancer Association Professional Committee of Urological and Reproductive Tumors. Two second class prize for Chinese Medical Science in 2014, scientific Chinese Outstanding Young Scientist Award in 2015.
"

Dr. Luis Llanes is graduated in Medicine and Surgery by the Autonomous University of Madrid in 1993. He received his doctoral degree from the Complutense University of Madrid in 2000. Currently, he is working as Head of the Urology Department at University Hospital of Torrejon (Madrid) and as Associate Professor in Urology, School of Medicine, Francisco de Vitoria University in Madrid (Spain). He is member of the European Association of Urology and Spanish Association of Urology. He published 67 articles in various international and national journals, and had an IF value of 81.96 with 131 citations to his articles. His research interests include Urologic Oncology, Endourology, Robotics & Minimally Invasive Urology.

Hereby I would like to follow your invitation and apply for Editorial Board Membership of SRL Urology. I studied medicine in Würzburg and work in the above mentioned department since 2009 in the field of molecular oncology (prostate cancer, renal cell carcinoma, urothelial carcinoma) and since 2013 in patient care.
My main research interests include moleculobiological oncologic research in urology (in detail microRNA expression in urological cancers) as well as clinical topics (clinical oncologic research in prostate-, renal- and urothelial carcinoma).